Ampicillin
/
|
Escherichia coli
|
See: Table II |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
42 |
|
51 |
No use |
50 |
|
59 |
|
Amoxicillin And Beta-Lactamase Inhibitor
/
|
Escherichia coli
|
See: Table II |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
0 |
|
51 |
No use |
4 |
|
59 |
|
Cefalotin
/
|
Escherichia coli
|
See: Table II |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
44 |
|
51 |
No use |
37 |
|
59 |
|
Cefuroxime
/
|
Escherichia coli
|
See: Table II |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
3 |
|
51 |
No use |
5 |
|
59 |
|
Cefoperazone
/
|
Escherichia coli
|
See: Table II |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
3 |
|
51 |
No use |
4 |
|
59 |
|
Ceftazidime
/
|
Escherichia coli
|
See: Table II |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
0 |
|
51 |
No use |
5 |
|
59 |
|
Streptomycin
/
|
Escherichia coli
|
See: Table II |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
51 |
|
51 |
No use |
57 |
|
59 |
|
Neomycin
/
|
Escherichia coli
|
See: Table II |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
0 |
|
51 |
No use |
2 |
|
59 |
|
Amikacin
/
|
Escherichia coli
|
See: Table II |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
0 |
|
51 |
No use |
0 |
|
59 |
|
Gentamicin
/
|
Escherichia coli
|
See: Table II |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
17 |
|
51 |
No use |
21 |
|
59 |
|
Tetracycline
/
|
Escherichia coli
|
See: Table II |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
33 |
|
51 |
No use |
47 |
|
59 |
|
Doxycycline
/
|
Escherichia coli
|
See: Table II |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
24 |
|
51 |
No use |
31 |
|
59 |
|
Chloramphenicol
/
|
Escherichia coli
|
See: Table II |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
21 |
|
51 |
No use |
34 |
|
59 |
|
Nitrofurantoin
/
|
Escherichia coli
|
See: Table II |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
2 |
|
51 |
No use |
8 |
|
59 |
|
Sulfamethoxazole And Trimethoprim
/
|
Escherichia coli
|
See: Table II |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
47 |
|
51 |
No use |
56 |
|
59 |
|
Norfloxacin
/
|
Escherichia coli
|
See: Table II |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
0 |
|
51 |
No use |
1 |
|
59 |
|
tet(A) (ARO:3000165)
/
|
Escherichia coli
|
See: Table IV |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
22 |
|
51 |
No use |
31 |
|
59 |
|
tet(B) (ARO:3000166)
/
|
Escherichia coli
|
See: Table IV |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
2 |
|
51 |
No use |
7 |
|
59 |
|
tet(C) (ARO:3000167)
/
|
Escherichia coli
|
See: Table IV |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
17 |
|
51 |
No use |
26 |
|
59 |
|
aadA (ARO:3002601)
/
|
Escherichia coli
|
See: Table IV |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
31 |
|
51 |
No use |
27 |
|
59 |
|
sul1 (ARO:3000410)
/
|
Escherichia coli
|
See: Table IV |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
29 |
|
51 |
No use |
9 |
|
59 |
|
sul2 (ARO:3000412)
/
|
Escherichia coli
|
See: Table IV |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
22 |
|
51 |
No use |
5 |
|
59 |
|
sul3 (ARO:3000413)
/
|
Escherichia coli
|
See: Table IV |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
19 |
|
51 |
No use |
23 |
|
59 |
|
dfrA1 (ARO:3002854)
/
|
Escherichia coli
|
See: Table IV |
AMR+ (n) |
AMR- (n) |
Total (n) |
Sulfonamide, co-trimoxazole (trimethoprim/sulfamethoxazole) and ampicillin use |
7 |
|
51 |
No use |
20 |
|
59 |
|